ÌÇÐÄÆƽâ°æ

Leading metabolic drugs by global revenue in 2025 (in million U.S. dollars)

© ÌÇÐÄÆƽâ°æ 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

April 2026

Region

Worldwide

Survey time period

2025

Supplementary notes

* Based on exchange rate as of April 20, 2026.

Citation formats

Leading metabolic products by global revenue 2025

Published by A. Minhas, Apr 20, 2026

The U.S.-based Eli Lilly and Danish company Novo Nordisk are the dominant players in the field of metabolic (diabetes and obesity) drugs. In 2025, Eli Lilly's drug Mounjaro was the leading diabetes and obesity product with revenue of about ** billion U.S. dollars. The second leading drug was Novo Nordisk's Ozempic, officially an antidiabetic but often used for weight loss, generating ** billion U.S. dollars globally. All the listed drugs can be classified as cardio-metabolic treatments, since, besides diabetes and obesity, they also target cardiovascular–renal risk.

Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

9

About the region

9

Selected statistics

10

Other regions

10

Related statistics

10

Further Content: You might find this interesting as well

Topics

Novo NordiskGlobal pharmaceutical industryPharmaceutical industry in the U.S.DiabetesDiabetes in China
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.